News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Epigenomics AG: Blood test shows promise in the detection of liver cancer

PDF -Results from two clinical studies demonstrate high sensitivity and specificity of mSEPT9 blood test -mSEPT9 test exhibited higher diagnostic accuracy than currently established diagnostic marker -Further independent, prospective clinical study with 440 patients initiated Berlin (Germany) and Germantown, MD (U.S.A.), April 19, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced promising results […]

Read more

Epigenomics AG Reports Results for Financial Year 2017

PDF Berlin (Germany) and Germantown, MD (U.S.A.), March 23, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), or the “Company”, today announced its financial results (according to IFRS) for the year ended December 31, 2017. KEY HIGHLIGHTS Financial Total revenue of EUR 1.9 million EBITDA (before share-based payment expenses) loss of EUR 9.4 […]

Read more

U.S. Senators Capito and Heinrich Introduce Bi-Partisan Colorectal Cancer Detection Bill

PDF Legislation aims to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests Berlin (Germany) and Germantown, MD (U.S.A.), March 8, 2018 – Senators Shelley Moore Capito (R -WV) and Martin Heinrich (D – NM), today introduced the “Colorectal Cancer Detection Act of 2018” to the United States Senate in […]

Read more

Epigenomics AG gets CE-IVD Mark for Lung Cancer Test Epi proLung®

PDF Berlin (Germany) and Germantown, MD (U.S.A.), December 19, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY, “Company”) announced today that it has received CE-IVD mark for its blood-based lung cancer test Epi proLung. Epi proLung is a highly innovative lung cancer test based on the combination of Epigenomics’ proprietary DNA methylation biomarkers. […]

Read more

Supervisory Board of Epigenomics AG Appoints Albert Weber as Executive Vice President Finance and a Member of the Management Board (Vorstand)

PDF Berlin (Germany) and Germantown, MD (U.S.A.), November 29, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced today that the Supervisory Board appointed Albert Weber Executive Vice President of Finance effective January 1, 2018.  Mr. Weber, who has worked at Epigenomics for the past seventeen years, will become a member of the Executive […]

Read more

Epigenomics AG announces recent payment decision by CMS

PDF Berlin (Germany) and Germantown, MD (U.S.A.), November 21, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) announced the Centers of Medicare & Medicaid Services(CMS) has changed their pricing determination for Epi proColon®, the first and only FDA-approved blood-based test for colorectal cancer (CRC) screening. In its recently published final payment determination for […]

Read more